Sartorius stock: analysis & valuation

SRT3.DEMedical Instruments & SuppliesGermanyData as of Nov 15, 2026
Metrics analysis · Medical Instruments & Supplies

Sartorius SRT3.DE

Price 290.50 EUR +1.18%Market cap 20.1 bn EUR52 weeks 198.50 – 299.30
Forward P/E
44.9x
Industry 18.5x
EV/EBITDA
25.5x
Industry 15.7x
Revenue growth
9.9%
Industry 4.7%
Operating margin
17.8%
Industry 12.9%
Return on equity
7.9%
Industry 6.3%
Free cash flow yield
1.9%
Industry 3.4%

What does Sartorius do?

Sartorius is a provider of products and services for biopharmaceutical manufacturing and laboratory research, headquartered in Göttingen. The company supplies consumables, equipment and software used in the development and production of biopharmaceuticals, such as bioreactors, filters, cell culture media, single-use bag systems and process monitoring solutions.

The business is divided into two segments: Bioprocess Solutions and Lab Products & Services. Customers are mainly pharmaceutical and biotechnology companies, contract development and manufacturing organizations, and academic research institutions. A large portion of revenue comes from recurring consumables needed in ongoing production processes. In terms of competition, Sartorius is among the leading providers of single-use technologies and filtration in bioprocessing and competes with large life science groups such as Thermo Fisher, Danaher and Merck KGaA, among others. Validated processes are usually closely tied to individual products, which binds customers over the long term.

Score profile

Quality4.9
Valuation3.3
Growth6.3
Financial strength1.7
Momentum9.4

Rank vs. Medical Instruments & Supplies (28 companies). 10 = top of the group, 5 = middle. Calculated from the metrics below, without AI.

Metrics compared with the industry

On profitability and quality, Sartorius ranks in the middle in the group Medical Instruments & Supplies (4.9/10). On growth, the company ranks above average in the group Medical Instruments & Supplies (6.3/10). On valuation (higher = cheaper), the stock ranks below average in the group Medical Instruments & Supplies (3.3/10). On financial strength, Sartorius ranks in the bottom fifth in the group Medical Instruments & Supplies (1.7/10).

MetricStockGroup medianRanking
Forward P/E44.9x18.5xbetter than 13 %
Trailing P/E94.3x34.2xbetter than 7 %
PEG ratio0.9x1.3xbetter than 69 %
EV/EBITDA25.5x15.7xbetter than 24 %
Price/sales5.5x3.1xbetter than 27 %
Price/book7.4x2.8xbetter than 13 %
Revenue growth9.9%4.7%better than 84 %
Earnings growth0.0%0.0%better than 43 %
Gross margin45.4%54.7%better than 30 %
Operating margin17.8%12.9%better than 70 %
Net margin6.0%8.5%better than 38 %
Return on equity7.9%6.3%better than 59 %
Debt/equity94.4%36.0%better than 13 %
Current ratio1.1x2.3xbetter than 13 %
Free cash flow yield1.9%3.4%better than 27 %
Dividend yield0.3%0.9%–
Payout ratio23.4%38.9%–
Beta1.510.85–

Valuation: what is Sartorius worth?

Two valuation approaches – a discounted cash flow model and a valuation at the industry’s median multiples – give Sartorius a model range of 120.05 EUR to 151.51 EUR per share.

Price 290.50 EUR
Analysts 297.50 EUR
Fair value range 120.05 EUR – 151.51 EURMidpoint 135.78 EUR (−53.3% vs. price)

20 analysts, average rating “Buy”, average price target 297.50 EUR (+2.4%).

The full DCF matrix, the reverse DCF (what growth the price implies) and scenarios are part of the Pro analysis.

What the business depends on

  • Demand depends on research and production activities in the biopharmaceutical industry, particularly in antibodies and new therapy types.
  • Recurring consumables in approved manufacturing processes provide predictable follow-on revenue once customers have adopted a product in production.
  • Pharma customers' willingness to invest and financing conditions for biotechnology affect sales of equipment and systems.

Risks

  • Restrained investment or inventory reduction at customers can significantly weigh on revenue and capacity utilization in the short term.
  • Strong competitors and possible pricing pressure from large customers can squeeze margins in the bioprocess business.
  • Dependence on regulatory-approved processes, global supply chains and currency effects makes planning more difficult.

What to look for with Sartorius

The ratio of orders received to revenue (book-to-bill) shows early on whether customer demand and inventory levels will support or weigh on future revenue development.

Full AI analysis of Sartorius

The AI evaluates all the numbers above and turns them into an assessment with a score, strengths and weaknesses, a fair value range and risks – from €1.99; Plus (€4.99) adds business model, moat and scenarios, Pro (€9.99) also peer comparison and reverse DCF. See an example.

Analyze a stock

Results in minutes
1 Choose a stock
2 Choose the depth

See what you get first: Example Compact (Apple) PDF Plus example (Microsoft) PDF Example Pro (NVIDIA) PDF

3 Delivery
Secure payment via Stripe Report by email + PDF No subscription

Frequently asked questions about Sartorius stock

What is the P/E ratio of Sartorius stock?

Based on expected earnings, Sartorius trades at a P/E of 44.9x, compared with a median of 18.5x for the peer group Medical Instruments & Supplies. Based on the earnings of the last twelve months it is 94.3x. (data as of Nov 15, 2026)

Does Sartorius pay a dividend?

Yes. The dividend yield is currently 0.3%, with a payout ratio of 23.4% of earnings.

Is Sartorius stock undervalued?

Measured by valuation metrics (P/E, EV/EBITDA, price/sales, PEG), Sartorius is currently valued more expensive than most companies in the group Medical Instruments & Supplies (valuation score 3.3 out of 10). Our model calculations (DCF and industry multiples) give a range of 120.05 EUR to 151.51 EUR per share at a price of 290.50 EUR. This is a model calculation, not an investment recommendation.

What do analysts say about Sartorius stock?

20 analysts have an average price target of 297.50 EUR (+2.4% vs. the current price); the average rating is “Buy”. Analyst targets are opinions and change frequently.

Comparable stocks

All information without guarantee. Metrics from public market data, updated daily; company profile written editorially with the help of AI. Not investment advice and not a solicitation to buy or sell securities.